Given that the effectiveness of immune checkpoint inhibitors (such as PD-1/PD-L1 inhibitors) is partially limited by TAMs, and that the CXCL9/10/11-CXCR3 axis is crucial for their anti-tumor effects [70], PU.1 inhibition could serve as an effective combinatory strategy with immune checkpoint inhibitor therapies. Here, CXCR3 is linked to neoplasm.